Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01015066
Other study ID # FMD04405009B
Secondary ID
Status Withdrawn
Phase Phase 4
First received October 15, 2009
Last updated June 6, 2014
Start date November 2009
Est. completion date June 2014

Study information

Verified date June 2014
Source State University of New York at Buffalo
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study is designed to determine the relative effectiveness of buprenorphine/naloxone (Suboxone) pharmacotherapy versus naltrexone pharmacotherapy for treatment retention, relapse prevention and opioid craving reduction among opioid-dependent adolescents and young adults. The investigators hypothesize that naltrexone treatment is as effective as buprenorphine/naloxone for these treatment outcomes.


Description:

Context: Standard treatment of opioid dependence in adolescents is detoxification and counseling, which results in relapse in 20-50% of patients. Alternative medical treatments include buprenorphine and naltrexone that have not been well investigated in adolescents and young adults. Buprenorphine has previously been shown effective in the treatment of opioid dependence in adolescents in one study in the United States as compared to detoxification. Although naltrexone treatment results in low compliance in adults, it is effective in combination with a strong social support network that exists in adolescents that live with at least 1 parent/guardian.

Objective: To compare the efficacy of buprenorphine/naloxone pharmacotherapy with naltrexone pharmacotherapy on treatment retention, relapse prevention and craving reduction among opioid-addicted adolescents and young adults.

Design: 2-arm Randomized Comparative Effectiveness Pharmacotherapy Clinical Trial.

Setting: The study will be conducted in an outpatient treatment facility Participants: The participants will be those who 1) are between 16-25 years old, 2) have clear evidence of a substance use disorder with opioid dependence, and 3) live with at least one parent.

Baseline data collection: Data collected at baseline will include (with examples), demographics (age, gender, race), substance use history (type of substances used, duration of use, routes of abuse), co-existing medical problems (seizures, hepatitis C), prior mental health problems (prior treatment, diagnoses), prior substance abuse treatment (outpatient, inpatient), socioeconomic variables (educational level, occupation, employment history), criminal history (number of arrests and convictions, total amount of time spent in jail or prison), family history (first degree relatives with substance use disorders) and scores on psychometric testing (DAST, opioid craving score).

Outcome data: Four main outcomes will be examined: Retention in treatment, self-reported opioid craving, self-reported drug use with urine toxicology confirmation. Retention in treatment (1-180 days) will be measured by the date that participant was last seen by study personnel or date when participant completes study following the date of enrollment. Opioid carving (1-10) will be measured by a 10 point visual analog scale. Self-reported drug use (days to first use and percent days abstinent) will be measured by time line follow back. Urine toxicology (yes/no) will be determined at baseline and monthly at 1, 2, 3, 4, 5, 6 months follow-up.

Data analysis: Outcome variables will be compared between the two groups using t-tests or chi-square tests as appropriate. A Kaplan-Myer survival analysis will be used to describe participant participation. Predictors of poor outcomes will be identified using a case-control design in which those with poor outcomes (the "cases") will be compared to those with successful outcomes (the "controls") using multivariate techniques (logistic regression).


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender Both
Age group 16 Years to 25 Years
Eligibility Inclusion Criteria:

- Clinical Diagnosis of Opiate Dependence

- Successful completion of detoxification

- can answer 9 out of 10 question correctly that tests understanding of the study

Exclusion Criteria:

- unable to pay for medication

- not living with a parent/guardian

- inability of patient and/or parent to give consent

- major co-occurring psychiatric disorder

- existing medical condition that would interfere with the treatment

- use of CNS depressants

- pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Buprenorphine/naloxone
Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)
Naltrexone
Oral tables, 50 mg/d, once a day for six months

Locations

Country Name City State
United States UB Department of Family Medicine Buffalo New York

Sponsors (1)

Lead Sponsor Collaborator
State University of New York at Buffalo

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Retention in treatment: (1-180 days) as measured by the date that participant was last seen by study personnel or date when participant completes study following the date of enrollment. 6 months No
Secondary Opioid craving: (1-10) as measured by a 10 point visual analog scale. 6 months No
Secondary Self-reported drug use: (days to first use and percent days abstinent) as measured by time line follow back. 6 months No
Secondary Urine toxicology: (yes/no) at baseline and monthly at 1, 2, 3, 4, 5, 6 months follow-up. 6 months No
See also
  Status Clinical Trial Phase
Completed NCT02539823 - Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans Phase 2
Recruiting NCT01934751 - Effectiveness of a Hospital Addiction Service in Treating Opioid and Alcohol Addiction N/A
Completed NCT00913770 - Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department N/A
Completed NCT00929253 - Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II) N/A
Terminated NCT02741076 - Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain Phase 4
Completed NCT03015597 - Pilot Study of Contingency Management for Smoking Cessation N/A
Completed NCT02571400 - Prevalence and Predictors of Prolonged Post-surgical Opioid Use: a Prospective Observational Cohort Study N/A
Terminated NCT00552578 - Buprenorphine as a Treatment in Opiate Dependent Pain Patients Phase 4
Completed NCT00253890 - Insomnia and Drug Relapse Risk Phase 3
Completed NCT02667158 - A Survey to Eval the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion
Completed NCT02667210 - Study to Eval Relation Btw Doctor/Pharmacy Shopping & Outcomes of Misuse, Diversion, Abuse, Addiction by Med Rec Review
Active, not recruiting NCT01021566 - Opiate Detoxification Using the Combined Hemoperfusion-hemodialysis Phase 3
Completed NCT02660619 - Validation of PRISM-5-Op, Measure Of Addiction To Prescription Opioid Medication
Active, not recruiting NCT02751762 - A Prospective Investigation of the Risks of Opioid Misuse, Abuse, and Addiction Among Patients Treated With Opioids for the Treatment of Chronic Pain
Completed NCT02657148 - Immediate Postpartum Nexplanon Placement in Opioid Dependent Women
Completed NCT02362256 - The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism N/A
Completed NCT01605539 - Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans Phase 2
Completed NCT00204243 - Naltrexone Implants vs. MMT Among Inmates in the Norwegian Correctional Services Phase 2
Completed NCT02667262 - An Observational Study to Develop Algorithms for Identifying Opioid Abuse and Addiction Based on Admin Claims Data
Completed NCT00829777 - Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects Phase 1